Allopurinol as a Cardiovascular Drug
- 1 November 2011
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Cardiology in Review
- Vol. 19 (6), 265-271
- https://doi.org/10.1097/crd.0b013e318229a908
Abstract
Cardiovascular disease (CVD) remains the leading cause of death in the United States. There is evidence that shows a direct relationship between an elevated uric acid level and an increased risk of cardiovascular (CV) events, which has set the foundation for the investigation of uric acid-lowering drugs for the treatment of CVD. Although traditionally the cornerstone therapy for gout, allopurinol's ability to be a competitive inhibitor of the key enzyme, xanthine oxidase, needed for uric acid formation, has prompted recent clinical research evaluating allopurinol as a CV drug. Epidemiologic and biochemical studies on uric acid formation have shown that it is not only uric acid itself that leads to worsening prognosis and increased CV events, but also the free radicals and superoxides formed during xanthine oxidase activity. The combination of uric acid formation and formed free radicals could ultimately lead to coronary endothelial dysfunction and worsening of myocardial oxidative stress. Along with preventing uric acid formation, allopurinol also has the ability to behave as a free radical scavenger of the superoxide anions and free radicals released during uric acid formation.Clinical studies have shown that allopurinol improves endothelial dysfunction and subsequently improves the exercise capacity in patients diagnosed with angina pectoris. Allopurinol has also been shown to decrease oxidative stress and ameliorate the morbidity and mortality of congestive heart failure patients by possibly improving mechanoenergetic uncoupling, with the enhancement of myocardial contractility and the left ventricular ejection fraction. This review presents the pharmacologic action of allopurinol on the CV system and describes the effectiveness of allopurinol as a potential drug to treat 2 CVD morbidities: ischemic heart disease and congestive heart failure.Keywords
This publication has 74 references indexed in Scilit:
- Allopurinol: A New Anti-Ischemic Role for an Old DrugJournal of the American College of Cardiology, 2011
- Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular RiskClinical Journal of the American Society of Nephrology, 2010
- Allopurinol for chronic stable angina: old drug, new tricks?The Lancet, 2010
- Uric Acid and Hypertension: Cause or Effect?Current Rheumatology Reports, 2010
- Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of AllopurinolPharmacological Reviews, 2006
- Serum Uric Acid and Cardiovascular MortalityJAMA, 2000
- Oxy free radical system in heart failure and therapeutic role of oral vitamin EInternational Journal of Cardiology, 1996
- Relation of Serum Uric Acid to Mortality and Ischemic Heart DiseaseAmerican Journal of Epidemiology, 1995
- Changes in insulin and lipid metabolism in males with asymptomatic hyperuricaemiaJournal of Internal Medicine, 1993
- Cardiovascular risk factors and obesity: Are baseline levels of blood pressure, glucose, cholesterol and uric acid elevated prior to weight gain?Journal of Chronic Diseases, 1985